Back to results
US 11,026,959 B2Granted
Synthetic composition and method for treating irritable bowel syndrome
AssigneeGlycom A/S
InventorsThierry Hennet, Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Life of this patent
Estimating the term…
Abstract
The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT).
Claims20
A method comprising:
- selecting an adult human patient with irritable bowel syndrome (IBS) experiencing one or more IBS symptoms;
- selecting an amount of a mixture of 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the adult human patient;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the adult human patient and reducing the likelihood of the adult human patient experiencing the one or more IBS symptoms by administering a daily dose of the selected effective amount of the mixture of 2′-FL and LNnT to the adult human patient.
1 more element
A method comprising:
- selecting a non-infant human patient who has been previously treated for one or more symptoms associated with irritable bowel syndrome (IBS);
- selecting an amount of a mixture of 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient and reducing in the non-infant human patient a risk of re-occurrence of one or more symptoms associated with IBS by administering a daily dose of the selected effective amount of the mixture of 2′-FL and LNnT and optionally one or more excipients, to the non-infant human patient, wherein the daily dose of the mixture is from about 2.5 g to about 20 g.
1 more element
A method comprising:
- selecting a non-infant human patient experiencing one or more symptoms associated with irritable bowel syndrome (IBS);
- selecting an amount of a mixture of 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human patient and reducing in the non-infant human patient the level of one or more inflammatory biomarkers or symptoms associated with the IBS by administering a daily dose of the selective effective amount of the mixture of 2′FL and LNnT to the non-infant human patient.
1 more element
Dependencies are inferred from the claim text.